Goldman Sachs analyst Salveen Richter upgraded Seattle Genetics (NASDAQ: SGEN) from Buy to Conviction Buy with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE